Preparing Pfizer-BioNTech Vaccine in Trusts

Ian Allen, Pharmacy Quality Assurance Regional Specialist (NW), North West Pharmaceutical Quality AssurancePublished Last updated See all updates

Resources to support the Pfizer-BioNTech Vaccine are provided including: standard operating procedures, work instructions and a checklist.

Purpose

Attached to this page are:

  • A standard operating procedure describing preparation of the vaccine
  • A preparation work instruction sheet for the vaccine
  • A supervision checklist for preparation of the vaccine

Presentation

The attachment is presented in Word to enable adaptation locally, or as reference source to check that existing local procedures are robust and comprehensive.
Within the SOP:

  • GREEN TEXT indicates that detail is awaited, and will be added when available;
  • RED TEXT indicates where detail is to be added locally.

Attachments

Other handling content for Trusts

Other COVID-19 vaccines resources

External Resources to Support Preperation

What to do if you still have questions

If you still have questions you can get in touch with us. However, please first read our service remit; and if you still think we can help, use the email address below.

We're supporting healthcare professionals in England with pharmaceutical aspects of the COVID-19 vaccination programme; read our service remit to find out more.
If you're a healthcare professional in England, get in touch with us if you still have questions

Change history

  1. VH8 Amended instructions for disposal of cartons to include placing in confidential waste
  1. VH8, VH8.1 and VH8.2 updated to describe withdrawal of 6 doses as standard practice
  1. VH8 Section 2 updated to include model of one person diluting and drawing up
  2. VH8 4.4.4 Now states “new” syringe / needle must be used
  3. VH8 4.1.7 addition of 2nd check to include correct vaccine vial selected
  4. VH8 4.4.1, VH8.1 and VH8.2 updated to include additional references to 6th dose
  1. Change to SOP VH8 Section 4.3.4, regarding presence of opaque particles prior to dilution
  2. VH8.1 updated to reflect the change
  1. Published